VolitionRx Ltd. is preparing a reimbursement submission for its Nu.Q Cancer assays to government agencies in France, a step that could lead to routine clinical use of the blood tests for lung cancer management. The submission will be actively supported by Hospices Civils de Lyon, France's second-largest university hospital system, and will run parallel with clinical certification processes at the institution.
Researchers at Hospices Civils de Lyon stated the Nu.Q Cancer test is intended for introduction into routine, reimbursed clinical practice for lung cancer management in France following completion of both reimbursement and certification processes. Data generated through collaboration with Volition indicates that measuring methylated nucleosome biomarkers at the time of non-small cell lung cancer diagnosis can provide information related to survival and disease progression. This approach may also help identify patients who could benefit from curative care.
The company expects to file the reimbursement submission under France's "Innovative Procedures Outside the Nomenclature" framework, which allows early reimbursement support for innovative medical procedures. Volition noted that reimbursement would represent a major milestone toward routine clinical use of Nu.Q Cancer assays in France and support broader commercialization and potential licensing discussions in other markets.
This development is significant because it represents progress toward making epigenetic blood testing more accessible in clinical settings. The ability to measure methylated nucleosome biomarkers could provide clinicians with additional tools for assessing lung cancer patients' prognosis and treatment needs. For patients, this could mean more personalized care approaches based on their specific disease characteristics.
The potential impact extends beyond France, as successful reimbursement and clinical adoption in one major healthcare market could influence decisions in other countries. The company's focus on developing simple, easy-to-use, cost-effective blood tests aligns with broader healthcare trends toward less invasive diagnostic methods. For more information about Volition, visit https://www.Volition.com.
Industry observers will be watching how this reimbursement process unfolds, as it could set precedents for how epigenetic testing is integrated into standard cancer care protocols. The collaboration with a major university hospital system like Hospices Civils de Lyon adds credibility to the clinical validation process and suggests confidence in the technology's potential clinical utility.
